Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) does about 517.11K shares in volume on a normal day but saw 108310461 shares change hands in the recent trading day. The company now has a market cap of 115.81M USD. Its current market price is $0.30, marking an increase of 6.48% compared to the previous close of $0.29. The 52 week high reached by this stock is $4.00 whilst the lowest price level in 52 weeks is $0.17. The script in recent trading has seen the stock touch a high of $1 and a low of $1.
Cyclacel Pharmaceuticals Inc (CYCC) has a 20-day trading average at $0.2353 and the current price is -92.41% off the 52-week high compared with 78.08% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.2854 and its 200-day simple moving average is $0.6765. If we look at the stock’s price movements over the week, volatility stands at 39.44%, which decreases to 18.99% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 62.30 to suggest the stock is neutral.
1 analysts observing the Cyclacel Pharmaceuticals Inc (CYCC) stock have set the 12-month price targets for the company’s shares at between $1 and $1. The consensus objective for the share price is $1.00, suggesting that the stock has a potential upside of 70.0% over the period. The median price target is 70.0% away from the current levels at $1.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Hold the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on July 18, 2022 when Oppenheimer resumed the stock to “Outperform” and issued a price target of $17.
The current price level is 29.11%, 6.44%, and -55.09% away from its SMA20, SMA50, and SMA200 respectively, with the CYCC price moving below the 50-day SMA on current market day. Cyclacel Pharmaceuticals Inc (CYCC) stock is up 34.66% over the week and 1.61% over the past month. Its price is -19.20% year-to-date and -81.01% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at 0 and 0 for whole year.
Its 12-month price target is $1. To reach the target analysts have set, the stock logically needs to grow 70.0 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $1, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $1.
Outstanding shares total 207.34M with insiders holding 51.09% of the shares and institutional holders owning 0.19% of the company’s common stock. The company has a return on equity of -807.39%. The beta has a value of 0.51. Price to sales ratio is 2895.25.
